[1] Nygaard B, Hegedüs L, Gervil M, et al. Influence of compensated radioiodine therapy on thyroidvolume and incidence of hypothyroidism in Graves′disease[J]. J Intern Med, 1995, 238(6):491-497.
[2] Farkasova T, Gurska S, Witkovsky V, et al. Significance of amino acid substitution variants of DNA repair genes in radiosusceptibility of cervical cancer patients; a pilot study[J]. Neoplasma, 2008, 55(4):330-337.
[3] Wang H, Zhu L, Gao J, et al. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells[J]. Oncol Rep, 2015, 33(1):403-412.
[4] Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor:mechanisms of activation and signalling[J]. Exp Cell Res, 2003, 284(1):31-53.  doi: 10.1016/S0014-4827(02)00098-8
[5] Toulany M, Kasten-Pisula U, Brammer I, et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair[J]. Clin Cancer Res, 2006, 12(13):4119-4126.  doi: 10.1158/1078-0432.CCR-05-2454
[6] Meijer TW, Kaanders JH, Span PN, et al. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy[J]. Clin Cancer Res, 2012, 18(20):5585-5594.  doi: 10.1158/1078-0432.CCR-12-0858
[7] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志, 2007, 46(10):876-882.  doi: 10.3760/j.issn:0578-1426.2007.10.035
[8] Asami K, Atagi S. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer[J]. World J Clin Oncol, 2014, 5(4):646-659.  doi: 10.5306/wjco.v5.i4.646
[9] Marti U, Ruchti C, Kämpf J, et al. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues[J]. Thyroid, 2001, 11(2):137-145.  doi: 10.1089/105072501300042785
[10] Bussink J, van der Kogel AJ, kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer[J]. Lancet Oncol, 2008, 9(3):288-296.  doi: 10.1016/S1470-2045(08)70073-1
[11] Nijkamp MM, Span PN, Terhaard CH, et al. Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial[J]. Eur J Cancer, 2013, 49(15):3202-3209.  doi: 10.1016/j.ejca.2013.06.024
[12] Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma[J]. Cancer Res, 2002, 62(24):7350-7356.
[13] Maurizi M, Almadori G, Ferrandina G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma[J]. Br J Cancer, 1996, 74(8):1253-1257.  doi: 10.1038/bjc.1996.525
[14] Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas:inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis[J]. Clin Cancer Res, 2000, 6(6):2166-2174.
[15] Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves′ patients treated with radioiodine:role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage[J]. J Clin Endocrinol Metab, 1998, 83(1):40-46.
[16] 谭建, 王澎, 张丽娟, 等. 131I治疗Graves病后早发甲低相关因素的综合分析[J].中华核医学杂志, 2005, 25(6):325-328.  doi: 10.3760/cma.j.issn.2095-2848.2005.06.001
[17] Zanotti-Fregonara P, Hindié E. On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2010, 37(12):2264-2266.  doi: 10.1007/s00259-010-1608-9
[18] Erem C, Kandemir N, Hacihasanoglu A, et al. Radioiodine treatment of hyperthyroidism:prognostic factors affecting outcome[J]. Endocrine, 2004, 25(1):55-60.